Literature DB >> 15315511

Pregabalin pharmacology and its relevance to clinical practice.

Elinor Ben-Menachem1.   

Abstract

Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system that exhibits potent anticonvulsant, analgesic, and anxiolytic activity in a range of animal models. In addition, pregabalin has been shown to be a highly effective adjunctive therapy for partial seizures in clinical trials. Potent binding to the alpha-2-delta site reduces depolarization-induced calcium influx with a consequential modulation in excitatory neurotransmitter release. Pregabalin has no demonstrated effects on GABAergic mechanisms. Pregabalin demonstrates highly predictable and linear pharmacokinetics, a profile that makes it easy to use in clinical practice. Absorption is extensive, rapid, and proportional to dose. Time to maximal plasma concentration is approximately 1 h and steady state is achieved within 24-48 h. These characteristics reflect the observed onset of efficacy as early as day two in clinical trials. High bioavailability, a mean elimination half life (t(1/2)) of 6.3 h, and dose-proportional maximal plasma concentrations and total exposures predict a dose-response relationship in clinical practice and allow an effective starting dose of 150 mg/day in clinical practice without need for titration. Administration with food has no clinically relevant effect on the amount of pregabalin absorbed, providing for a dosing regimen uncomplicated by meals. Pregabalin does not bind to plasma proteins and is excreted virtually unchanged (<2% metabolism) by the kidneys. It is not subject to hepatic metabolism and does not induce or inhibit liver enzymes such as the cytochrome P450 system. Therefore, pregabalin is unlikely to cause, or be subject to, pharmacokinetic drug-drug interactions--an expectation that has been confirmed in clinical pharmacokinetic studies. However, dose adjustment may be necessary in patients with renal insufficiency. Thus, the pharmacological and pharmacokinetic profiles of pregabalin provide a predictable basis for its use in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315511     DOI: 10.1111/j.0013-9580.2004.455003.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  114 in total

1.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 2.  [Pregabalin and postoperative hyperalgesia. A review].

Authors:  A J Lederer; H Bornemann-Cimenti; M Wejbora; C Kern-Pirsch; K Michaeli; A Sandner-Kiesling
Journal:  Schmerz       Date:  2011-02       Impact factor: 1.107

Review 3.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?

Authors:  Michael Camilleri
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

Review 5.  Pregabalin in the treatment of chronic pain: an overview.

Authors:  S Chiechio; M Zammataro; F Caraci; L Rampello; A Copani; A F Sabato; F Nicoletti
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 6.  Pregabalin: as adjunctive treatment of partial seizures.

Authors:  Greg Warner; David P Figgitt
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.

Authors:  Johanna Iturrino; Michael Camilleri; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Liver Dis       Date:  2013-10-04       Impact factor: 4.088

9.  Efficacy and Safety of Pregabalin for the Treatment of Neuropathic Pain in Patients Undergoing Hemodialysis.

Authors:  Tomoyasu Otsuki; Terumi Higuchi; Toshio Yamazaki; Erina Okawa; Kazuyoshi Okada; Masanori Abe
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

10.  Diagnosis and treatment of glossopharyngeal and vagal neuropathies in a patient with laryngopharyngeal reflux.

Authors:  Irina Lokshina; Igor Feinstein; Carole Agin; Robert Katz
Journal:  Anesthesiology       Date:  2008-10       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.